Ye Guo

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yunpeng Yang, Jianji Pan, Hui Wang et al. · Cancer Cell · 2023 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

Yuxiang Ma, Yan Huang, Yuanyuan Zhao et al. · The Lancet Oncology · 2024 · 121 citations

Medicine, Oncology, Pharmacology +14

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Runxia Gu, Fang Liu, Dehui Zou et al. · Journal of Hematology & Oncology · 2020 · 112 citations · Full text

Life Sciences, Immunology, Oncology +17

Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer

Yu‐Juan Zhang, Donghong Zhang, Fei Wang et al. · Scientific Reports · 2015 · 106 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China

Zhitao Ying, Haiyan Yang, Ye Guo et al. · Cancer Medicine · 2020 · 100 citations · Full text

Medicine, Clinical Pharmacokinetics, Oncology +17